The cooperation agreement opens the door to the generation of new business opportunities for other disruptive technologies created at IQS’s laboratories
Dr. Pedro Regull, Managing Director of IQS, a university center leader in innovative technologies in chemistry, biotechnology and engineering; and Prof. Dr. Sergi Trilla, CEO of trifermedCBDO, company specialized in business development in the health sector, have signed this week a cooperation agreement in Barcelona in order to develop and bring to market a leading boadhesive technology.
The technology, conceived and developed by Dr. Salvador Borrós at the Laboratory of Biomaterials of IQS, is born with the aim to develop a commercial version of different types of adhesives for biomedical applications, that contribute to the improvement of different surgical processes. It is expected that by 2019, the global boadhesives market will reach 6 billion dollars, with a 13% annual growth.
The cooperation agreement in this new boadhesive technology is the beginning of a long-term collaboration in which both parts join their efforts to bring disruptive technologies to market. IQS y trifermedCBDO will work together to satisfy industry and society needs.
The agreement between IQS and trifermedCBDO has been sealed with the conviction that both parties will be able to provide the best of their know-how and experience to achieve the defined milestones. IQS will provide its scientific research and innovative capacity through its research teams in the field of life-science technologies, such as health, pharmacy and biotechnology. Meanwhile, trifermedCBDO, through its extensive experience in life-sciences business development and its presence in the European and North American markets, will design business models and validate their viability with selected international partners. This agreement strengthens technological transfer between university research and companies.
In the words of Dr. Regull: “First of all, this alliance gives IQS a market-oriented approach that helps us define goals and research lines. At the same time, we rely on an expert partner in business models which, once validated internationally, they become the essential key for the knowledge transfer from university research to industry”.
In that regard, Dr. Trilla adds: “It’s a privilege for us to have the opportunity to collaborate with an institution like IQS. There are many companies worldwide looking for technologies that solve common problems of the medical professionals. To be able to have access to this type of technologies that IQS developes for this, is an opportunity for us since we can offer them a methodology and an international projection that until now was not available to them.
In the formalization of this agreement has also participated the lawyer Àlvar Bertolin with the attorney’s office Torralba, Bertolín & Farré, who has acted as legal advisor.
